119 related articles for article (PubMed ID: 11551406)
21. The use of neuroendocrine immunoperoxidase markers to predict chemotherapy response in patients with non-small-cell lung cancer.
Graziano SL; Mazid R; Newman N; Tatum A; Oler A; Mortimer JA; Gullo JJ; DiFino SM; Scalzo AJ
J Clin Oncol; 1989 Oct; 7(10):1398-406. PubMed ID: 2550590
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
23. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
[TBL] [Abstract][Full Text] [Related]
24. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
[TBL] [Abstract][Full Text] [Related]
25. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma.
Pelosi G; Pasini F; Sonzogni A; Maffini F; Maisonneuve P; Iannucci A; Terzi A; De Manzoni G; Bresaola E; Viale G
Cancer; 2003 May; 97(10):2487-97. PubMed ID: 12733148
[TBL] [Abstract][Full Text] [Related]
26. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
[TBL] [Abstract][Full Text] [Related]
27. Results after surgery in undifferentiated large cell carcinoma of the lung: the role of neuroendocrine expression.
Wertzel H; Grahmann PR; Bansbach S; Lange W; Hasse J; Böhm N
Eur J Cardiothorac Surg; 1997 Nov; 12(5):698-702. PubMed ID: 9458138
[TBL] [Abstract][Full Text] [Related]
28. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer.
Rusch V; Klimstra D; Venkatraman E; Oliver J; Martini N; Gralla R; Kris M; Dmitrovsky E
Cancer Res; 1995 Nov; 55(21):5038-42. PubMed ID: 7585548
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
[TBL] [Abstract][Full Text] [Related]
30. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
[TBL] [Abstract][Full Text] [Related]
31. p53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer.
Fijołek J; Wiatr E; Rowińska-Zakrzewska E; Giedronowicz D; Langfort R; Chabowski M; Orłowski T; Roszkowski K
Int J Biol Markers; 2006; 21(2):81-7. PubMed ID: 16847810
[TBL] [Abstract][Full Text] [Related]
32. Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.
Shaw GL; Gazdar AF; Phelps R; Linnoila RI; Ihde DC; Johnson BE; Oie HK; Pass HI; Steinberg SM; Ghosh BC
Cancer Res; 1993 Nov; 53(21):5181-7. PubMed ID: 8221655
[TBL] [Abstract][Full Text] [Related]
33. The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients.
Kim YC; Park KO; Kern JA; Park CS; Lim SC; Jang AS; Yang JB
Lung Cancer; 1998 Dec; 22(3):181-90. PubMed ID: 10048471
[TBL] [Abstract][Full Text] [Related]
34. Biological prognostic factors for early stage completely resected non-small cell lung cancer.
Cagini L; Monacelli M; Giustozzi G; Moggi L; Bellezza G; Sidoni A; Bucciarelli E; Darwish S; Ludovini V; Pistola L; Gregorc V; Tonato M
J Surg Oncol; 2000 May; 74(1):53-60. PubMed ID: 10861611
[TBL] [Abstract][Full Text] [Related]
35. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
Huang PY; Liang XM; Lin SX; Luo RZ; Hou JH; Zhang L
Ai Zheng; 2004 Jul; 23(7):845-50. PubMed ID: 15248926
[TBL] [Abstract][Full Text] [Related]
36. Do molecular markers predict survival in non-small-cell lung cancer?
Greatens TM; Niehans GA; Rubins JB; Jessurun J; Kratzke RA; Maddaus MA; Niewoehner DE
Am J Respir Crit Care Med; 1998 Apr; 157(4 Pt 1):1093-7. PubMed ID: 9563724
[TBL] [Abstract][Full Text] [Related]
37. [The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer].
Hirai Y; Shimizu Y; Oura S; Yoshimasu T; Ota F; Nakamura R; Naito K; Nishiguchi H; Hashimoto S; Okamura Y
Gan To Kagaku Ryoho; 2012 Mar; 39(3):381-4. PubMed ID: 22421763
[TBL] [Abstract][Full Text] [Related]
38. [p53 and HER-2/neu expression in relation to chemotherapy in non-small cell lung cancer patients].
Fijołek J
Pneumonol Alergol Pol; 2003; 71(7-8):365-70. PubMed ID: 15052971
[No Abstract] [Full Text] [Related]
39. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer.
Tsao MS; Aviel-Ronen S; Ding K; Lau D; Liu N; Sakurada A; Whitehead M; Zhu CQ; Livingston R; Johnson DH; Rigas J; Seymour L; Winton T; Shepherd FA
J Clin Oncol; 2007 Nov; 25(33):5240-7. PubMed ID: 18024870
[TBL] [Abstract][Full Text] [Related]
40. Influence of apoptosis and cell cycle regulator proteins on chemotherapy response and survival in stage IIIA/IIIB NSCLC patients.
Morero JL; Poleri C; Martín C; Van Kooten M; Chacón R; Rosenberg M
J Thorac Oncol; 2007 Apr; 2(4):293-8. PubMed ID: 17409800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]